Study Review – Bimekizumab efficacy in high-impact areas

As part of our ongoing aim to bring you reports of new developments, we have added a review which examined the efficacy of bimekizumab in patients with moderate to severe plaque psoriasis in high-impact areas (scalp, nails, palms and soles), across five phase 3/3b trials. The analysis reports on the results from an interim analysis encompassing up to 2 years of data from the BE VIVID, BE READY and BE SURE trials, and their ongoing open-label extensions BE BRIGHT and BE RADIANT.

Independent commentary for the review has been provided by Dr Hugh Roberts, a consultant dermatologist at the Victorian Melanoma Service, part of the Paula Fox Melanoma and Cancer Centre at the Alfred Hospital.